{"&cites=16656632348319106054&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1712126","authors":["RJ Motzer","RJ Motzer NM Tannir","RJ Motzer NM Tannir DF McDermott…"],"year":2018,"numCitations":1247,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1712126","citationUrl":"http://scholar.google.com/scholar?cites=13898631485117911629&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:TVKDlrLb4cAJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13898631485117911629&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc","p":1,"exp":1596898395510},{"title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816714","authors":["BI Rini","BI Rini ER Plimack","BI Rini ER Plimack V Stus","BI Rini ER Plimack V Stus R Gafanov…"],"year":2019,"numCitations":545,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816714","citationUrl":"http://scholar.google.com/scholar?cites=14370914940926626173&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:fQlJl_--b8cJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14370914940926626173&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816047","authors":["RJ Motzer","RJ Motzer K Penkov","RJ Motzer K Penkov J Haanen","RJ Motzer K Penkov J Haanen B Rini…"],"year":2019,"numCitations":502,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816047","citationUrl":"http://scholar.google.com/scholar?cites=1882792696390332365&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:za8LXvsFIRoJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1882792696390332365&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1803675","authors":["A Méjean","A Méjean A Ravaud","A Méjean A Ravaud S Thezenas…"],"year":2018,"numCitations":332,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1803675","citationUrl":"http://scholar.google.com/scholar?cites=2759106540828352675&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:o-CHz8dQSiYJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=2759106540828352675&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Treatment of renal cell carcinoma: current status and future directions","url":"https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.3322/caac.21411","authors":["PC Barata","PC Barata BI Rini"],"year":2017,"numCitations":165,"pdf":"https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21411","citationUrl":"http://scholar.google.com/scholar?cites=7801829241769079319&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:F7LmCVyqRWwJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=7801829241769079319&hl=en&as_sdt=2005&sciodt=0,5","publication":"Wiley Online Library"},{"title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase …","url":"https://www.sciencedirect.com/science/article/pii/S0140673619307238","authors":["BI Rini","BI Rini T Powles","BI Rini T Powles MB Atkins","BI Rini T Powles MB Atkins B Escudier…"],"year":2019,"numCitations":181,"pdf":"https://researchers.mq.edu.au/en/publications/atezolizumab-plus-bevacizumab-versus-sunitinib-in-patients-with-p","citationUrl":"http://scholar.google.com/scholar?cites=16381744679535091864&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:mKDV6P2lV-MJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16381744679535091864&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose …","url":"https://www.sciencedirect.com/science/article/pii/S1470204518301074","authors":["TK Choueiri","TK Choueiri J Larkin","TK Choueiri J Larkin M Oya","TK Choueiri J Larkin M Oya F Thistlethwaite…"],"year":2018,"numCitations":124,"citationUrl":"http://scholar.google.com/scholar?cites=6306462962101346356&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:NGA1paYOhVcJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6306462962101346356&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial) …","url":"https://www.sciencedirect.com/science/article/pii/S0959804918301813","authors":["TK Choueiri","TK Choueiri C Hessel","TK Choueiri C Hessel S Halabi","TK Choueiri C Hessel S Halabi B Sanford…"],"year":2018,"numCitations":121,"pdf":"https://www.sciencedirect.com/science/article/pii/S0959804918301813","citationUrl":"http://scholar.google.com/scholar?cites=14929455411752643417&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:WauM65gUMM8J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14929455411752643417&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell …","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946714/","authors":["KD Courtney","KD Courtney JR Infante","KD Courtney JR Infante ET Lam…"],"year":2018,"numCitations":105,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946714/","citationUrl":"http://scholar.google.com/scholar?cites=7656214066233453293&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:7aox_iBWQGoJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=7656214066233453293&hl=en&as_sdt=2005&sciodt=0,5","publication":"ncbi.nlm.nih.gov"},{"title":"Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer","url":"https://discovery.ucl.ac.uk/id/eprint/10073239/","authors":["TK Choueiri","TK Choueiri E Plimack","TK Choueiri E Plimack HT Arkenau…"],"year":2017,"numCitations":84,"pdf":"https://discovery.ucl.ac.uk/id/eprint/10073239/1/JCO%20CHOUEIRI%202017%20FINAL%20PUBLISHED%20Phase%202.pdf","citationUrl":"http://scholar.google.com/scholar?cites=8217983595098648878&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:LrHX-4kkDHIJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8217983595098648878&hl=en&as_sdt=2005&sciodt=0,5","publication":"discovery.ucl.ac.uk"}]}